A recent systematic review of scientific literature suggests that cannabidiol (CBD), a non-intoxicating compound derived from the cannabis plant, holds potential as an anticancer agent for dogs. This comprehensive analysis, published in the journal Frontiers in Veterinary Science, compiles existing preclinical evidence, indicating that CBD may influence various canine cancer types.
The review highlights that while the impact of cannabidiol on canines has been less extensively studied compared to humans, preliminary research consistently points to its potential. Authors affiliated with the University of Chile noted that CBD has been shown to be well-tolerated and safe in dogs, supporting further exploration of its clinical applications.
Understanding Cannabidiol’s Role in Canine Oncology
The systematic review focused on preclinical studies, primarily utilising cellular models, to investigate the effects of CBD on different canine cancers. Researchers examined findings related to lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma.
- Antiproliferative Effects: Studies consistently indicate that CBD may inhibit the growth and spread of cancer cells.
- Proapoptotic Effects: Cannabidiol appears to induce apoptosis, a process of programmed cell death, in various tumour cells.
- Intracellular Signalling: In some instances, these effects are associated with the modulation of intracellular signalling pathways.
The review also observed that combining CBD with other therapeutic agents has shown both synergistic (enhancing effects) and antagonistic (reducing effects) outcomes, underscoring the complexity of cannabinoid interactions within biological systems. These findings collectively suggest the potential of cannabidiol for canine cancer management, though the mechanisms require further elucidation.
Broader Context of Cannabinoid Research
The investigation into CBD’s potential in canine oncology builds upon a growing body of research exploring cannabinoids in cancer treatment for humans. Another recent scientific review, for example, indicated that CBD holds promise as an anti-tumour agent, alongside its known anti-inflammatory properties. Scientists have explored CBD’s effects on aggressive cancers such as glioblastoma, as well as breast, lung, colorectal, ovarian, and prostate cancers, suggesting it may help in suppressing their growth and metastasis.
A paper published in the journal Pharmacology & Therapeutics assessed a range of clinical and preclinical findings, suggesting that the efficacy of certain chemotherapy drugs could potentially be enhanced by medical cannabis. Furthermore, a study conducted last year reported that patients with cancer using cannabis often experience significant improvements in cancer-related symptoms, aligning with anecdotal reports and patient interest, as previously covered by Hemp Gazette in our guide to Cannabinoid Clinical Trials.
Safety and Future Directions
The safety profile of CBD in dogs is an important consideration. The National Animal Supplement Council (NASC) promoted a study in 2024 that suggested CBD is safe for long-term use in dogs. This finding is significant given emerging research into cannabis’s potential to address conditions such as anxiety and certain skin diseases in canines. For instance, a 2024 case study indicated that cannabis may be a viable alternative treatment option for dogs suffering from a common skin condition, particularly when conventional steroid therapies lead to adverse side effects.
Despite the encouraging preclinical findings regarding cannabidiol for canine cancer, researchers emphasise the need for further studies. These future investigations are crucial to better understand the underlying mechanisms, standardise concentrations and formulations, and enable reliable, comparable results. Ultimately, this will pave the way for robust clinical studies to fully evaluate the role of CBD in veterinary oncology, ensuring evidence-based approaches for pet health.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
